Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22601424 | 0.82 | SLC7A5 (0.39) | TSHRSLC7A5PSMB5 | |
| SCHEMBL20747635 | 0.78 | LMNA (0.37) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| SCHEMBL25989500 | 0.76 | LMNA (0.42) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| SCHEMBL22601580 | 0.75 | CYP4F2 (0.34) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| SCHEMBL24943430 | 0.72 | LMNA (0.35) | LMNAHSD17B10TSHRCYP3A4NFKB1 | |
| SCHEMBL1515227 | 0.72 | TSHR (0.50) | TSHRRAB9ATDP1SLC7A5PSMB5 | |
| SCHEMBL15148055 | 0.72 | TSHR (0.50) | TSHRRAB9ATDP1SLC7A5PSMB5 | |
| SCHEMBL10363386 | 0.72 | TSHR (0.50) | TSHRRAB9ATDP1SLC7A5PSMB5 | |
| SCHEMBL26143811 | 0.72 | SLC7A5 (0.44) | TSHRSLC7A5PSMB5 | |
| SCHEMBL1204246 | 0.72 | TSHR (0.37) | TSHRADRA1ATDP1SLC7A5PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | LMNA 3233/4885HSD17B10 2536/4885TSHR 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.